Abstract: The platelet inhibitory effect of antiplatelet agents varies widely among individuals. Some of the patients receiving antiplatelet drugs still have high platelet reactivity and high platelet reactivity is associated with adverse clinical outcomes. Platelet aggregation function monitoring has been proposed to guide antiplatelet therapy. In recent years, research has been performed to evaluate the clinical impact of more intensive antiplatelet therapy based on platelet reactivity testing, but two opposite conclusions have been drawn. Better research should be designed to verify the clinical significance of platelet function testing.